PAM50 Spanish Startup Aims to Develop Novel Genomic Tests to Guide Breast Cancer Treatment Premium Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision. GenomeDx Datasharing System Yields New Insights; Challenges Dx Development Paradigms Premium A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic. Cigna to Cover NanoString Prosigna Breast Cancer Test The insurer is the latest to provide coverage for NanoString's gene expression-based breast cancer recurrence risk test. Noridian Issues Favorable LCD for NanoString's Prosigna Breast Cancer Assay The finalized guidance follows a similar favorable LCD from Medicare contractor Palmetto, enabling reimbursement for Prosigna in a total of 39 US states. ESMO Clinical Practice Guidelines Recommend NanoString's Prosigna Assay The clinical practice guidelines include the PAM50 gene expression signature, which the Prosigna Assay is based on, as a predictive tool for chemotherapy benefit. Aug 13, 2015 Medicare Contractor Issues Favorable Final LCD for NanoString Prosigna Test Dec 8, 2014 FDA Updates Labeling for NanoString's Prosigna Test Oct 29, 2014 NanoString Study Shows Prosigna Can Assess Breast Cancer Patients' Risk of Late, Distant Recurrence Premium Mar 5, 2014 NanoString Focused on Growing Prosigna Adoption, Reimbursement Premium Feb 12, 2014 NanoString Publication Suggests Prosigna Can Assess Late Distant Breast Cancer Recurrence Premium Sep 11, 2013 Agendia Study Suggests Subset of ER+ Breast Cancer Patients May Be Mistreated without Molecular Subtyping Premium Jul 10, 2013 Validation Study for NanoString Prosigna Recurrence Test Published in JCO Premium Feb 20, 2013 MDx/CDx Focus: NanoString Launches Prosigna in EU, Israel; Diagnovus Launches DLBCL Prognostic Test Premium Dec 12, 2012 Personalized Medicine Highlights from San Antonio Breast Cancer Symposium 2012 Premium May 16, 2012 MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth Launches ConfirmMDx Premium Dec 14, 2011 NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX Premium Jul 27, 2011 St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping Premium May 18, 2011 Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group Premium Jan 20, 2011 Dx Focus Jan 20, 2011: Clinical and Regulatory PCR and Nucleic Acid Testing News Premium Dec 9, 2010 Bioclassifier, NanoString to 'Decentralize' Breast Cancer Test as ARUP Preps qPCR Version Premium Breaking News Ancient DNA Analysis Highlights Three Ancestral Populations in Japan FDA Warns of Potential False Positives With Abbott SARS-CoV-2 Molecular Tests New Products Posted to GenomeWeb: Oxford Nanopore, Beckman Coulter, Thermo Fisher Scientific, More People in the News: New Appointments at Sema4, NHGRI, Dante Labs, Ancestry, More Thermo Fisher Scientific Expects 12 Percent Revenue Growth in 2022 In Brief This Week: Myriad Genetics, Danaher, Co-Diagnostics, and More The Scan For Those Thick Tiger Stripes Tigers in India with thick stripes harbor a genetic change, as Gizmodo reports. High GABA Tomatoes The Japan News reports that genome-edited tomatoes with higher GABA levels are now for sale in Japan. Approach for Inclusivity and Diversity A National Human Genome Research Institute team calls for the field to "adopt diversity as an ethos." Science Papers on Tumors Immune System Evasion; Drivers of Genomic Instability, Inflammation In Science this week: study of how tumors evade the adaptive immune system, and more.